A detailed history of Dynamic Technology Lab Private LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Dynamic Technology Lab Private LTD holds 1,154 shares of VRTX stock, worth $596,317. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,154
Holding current value
$596,317
% of portfolio
0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $453,302 - $560,301
1,154 New
1,154 $541,000
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $2.04 Million - $2.3 Million
7,140 New
7,140 $2.06 Million
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $1.39 Million - $1.75 Million
-7,831 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $1.42 Million - $1.59 Million
7,831 New
7,831 $1.42 Million
Q1 2020

May 13, 2020

SELL
$199.77 - $247.81 $221,345 - $274,573
-1,108 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $346,256 - $465,061
-2,077 Reduced 65.21%
1,108 $243,000
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $529,442 - $595,881
3,185 New
3,185 $540,000
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $210,711 - $245,762
-1,446 Closed
0 $0
Q1 2018

Jun 14, 2018

SELL
$151.6 - $177.13 $131,437 - $153,571
-867 Reduced 37.48%
1,446 $235,000
Q1 2018

May 14, 2018

BUY
$151.6 - $177.13 $350,650 - $409,701
2,313 New
2,313 $376,000
Q4 2017

Feb 09, 2018

SELL
$137.28 - $155.55 $483,088 - $547,380
-3,519 Closed
0 $0
Q3 2017

Nov 08, 2017

SELL
$148.13 - $162.24 $231,230 - $253,256
-1,561 Reduced 30.73%
3,519 $535,000
Q2 2017

Aug 17, 2017

BUY
N/A
5,080
5,080 $654,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.